5 Pro-Life Companies to Invest In

4. Haemonetics Corporation (NYSE:HAE)

Blood and plasma supplies and services company Haemonetics Corporation (NYSE:HAE) was one of those rare stocks that managed to outperform the market in 2022 by huge margins. Haemonetics Corporation (NYSE:HAE) is up about 43% over the past year. Ave Maria Value Fund has a $13.6 million stake in the company.

For the fiscal second quarter of 2023, the Massachusetts-based company easily beat expectations, posting non-GAAP EPS of $0.83, which was $01.6 above estimates. Revenue in the quarter jumped about 24% and totaled $297.48 million, beating analyst estimates by $28.26 million. The company also updated its previous fiscal 2023 GAAP total revenue growth guidance from 8% – 11% to 12% – 15% vs. consensus growth of 10%.

Haemonetics is also gaining ground among the smart money. 25 hedge funds of the 920 funds tracked by Insider Monkey ended the third quarter of last year with Haemonetics Corporation (NYSE:HAE) in their portfolios, compared to 20 funds in the previous quarter.

Here is what Heartland Value Plus Fund has to say about Haemonetics Corporation (NYSE:HAE) in its Q2 2022 investor letter:

“Haemonetics, which provides disposables and devices used for blood and plasma collection, appears to be a recession-friendly stock as its products are not economically dependent. Moreover, as households feel economic pressures, they are more likely to donate plasma, for which they are compensated.”